From Wikipedia, the free encyclopedia
Vaccine adjuvant now being trialed as an Alzheimer's vaccine at Brigham and Women's
Protollin is a
drug initially formulated as a
vaccine adjuvant .
[1]
[2] It is composed of
lipopolysaccharides derived from the
Shigella flexneri or
Pleisiomonas shigelloides bacterium combined with
hydrophobic outer membrane proteins derived from
Neisseria meningitidis .
[3]
[4]
On November 16, 2021,
Brigham and Women's Hospital announced that it was beginning a
Phase I clinical trial of Protollin as a nasally-delivered vaccine to activate the body's immune response against amyloid proteins that form in the brain and are thought to contribute to the symptoms of Alzheimer's disease.
[5]
[6]
References
^
"Human trials for nasal Alzheimer's vaccine due to start" .
Newsweek . 2021-11-17. Retrieved 2021-11-19 .
^
"First human trial of Alzheimer's disease nasal vaccine to begin at Boston hospital" . www.cbsnews.com .
CBS News . 16 November 2021. Retrieved 2021-11-19 .
^ JONES, T; ADAMOVICZ, J; CYR, S; BOLT, C; BELLEROSE, N; PITT, L; LOWELL, G; BURT, D (2006-03-06).
"Intranasal Protollin™/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection" . Vaccine . 24 (10): 1625–1632.
doi :
10.1016/j.vaccine.2005.09.052 .
ISSN
0264-410X .
PMID
16243411 .
^ Jones, Taff; Cyr, Sonya; Allard, Francine; Bellerose, Nathalie; Lowell, George H; Burt, David S (September 2004).
"Protollin™: a novel adjuvant for intranasal vaccines" . Vaccine . 22 (27–28): 3691–3697.
doi :
10.1016/j.vaccine.2004.03.035 .
PMID
15315848 .
^
"BWH Press Release - Brigham and Women's Hospital" . www.brighamandwomens.org . Retrieved 2021-11-18 .
^ Jones, Taff; Cyr, Sonya; Allard, Francine; Bellerose, Nathalie; Lowell, George H.; Burt, David S. (2004-09-09).
"Protollin: a novel adjuvant for intranasal vaccines" . Vaccine . 22 (27–28): 3691–3697.
doi :
10.1016/j.vaccine.2004.03.035 .
ISSN
0264-410X .
PMID
15315848 .